内部人出售Axsome和Avidity的股票,收入和股票下降情况不一。 Insiders sold shares at Axsome and Avidity amid mixed earnings and stock declines.

2026年1月21日至22日, Axsome治疗和Avidity生物科学公司的多个内部人士与Axsome的CFO和另一个内部人士共同处置了19 500多股股票。 On January 21-22, 2026, multiple insiders at Axsome Therapeutics and Avidity Biosciences sold shares, with Axsome’s CFO and another insider collectively disposing of over 19,500 shares. Axomes报告说,尽管收入增长63.2%,但每股损失了0.94美元的Q3,低于估计数。 Axsome reported a Q3 loss of $0.94 per share, below estimates, despite 63.2% revenue growth. Avidiity指出,尽管收入猛增42.8%,但Q3每股损失1.27美元,预测缺失。 Avidity posted a Q3 loss of $1.27 per share, missing forecasts, though revenue jumped 420.8%. 两家公司都看到股票在混合收入中下跌,Axomes的股位接近12个月高,Avidity的交易接近52周的高峰。 Both companies saw stock declines amid mixed earnings, with Axsome’s shares near a 12-month high and Avidity’s trading near its 52-week peak. 分析师认为Axsome的评级为"中等购买",而Avidity的评级为"持有",理由是药品标签可能扩大和收入增长强. Analysts maintain a “Moderate Buy” rating for Axsome and a “Hold” rating for Avidity, citing potential drug label expansions and strong revenue growth.